eligibility_summary
Adults 18–70 with confirmed TNBC (ER/PR<10%, HER2− per 2018 ASCO‑CAP), locally advanced/metastatic post‑surgery with 1–2 prior lines or early relapse ≤1 yr after (neo)adjuvant. No prior immunotherapy/anti‑angiogenics. ≥1 RECIST lesion, ECOG 0–2, >12‑wk survival, adequate organ function (LVEF≥50%), stable/asymptomatic brain mets allowed, contraception required. Exclude uncontrolled CNS/effusions, recent trials/other cancers, major cardiac/thrombotic/GI events, malabsorption, drug allergy, active HIV/HBV/HCV, pregnancy, uncontrolled comorbidity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06878625 tests Trop-2 ADC–based combinations in ≥2nd-line TNBC. Interventions: 1) Sacituzumab govitecan (ADC): anti–Trop-2 monoclonal antibody linked to SN-38 (topoisomerase I inhibitor). Delivers cytotoxic SN-38 to Trop-2–expressing tumor cells and nearby cells (bystander effect), causing DNA damage. 2) Toripalimab (immune checkpoint inhibitor): anti–PD-1 monoclonal antibody that blocks PD-1/PD-L1, reactivating antitumor T cells. 3) Bevacizumab (anti-angiogenic mAb): binds VEGF-A, blocking VEGFR signaling to inhibit tumor angiogenesis. 4) Anlotinib (small-molecule multi-kinase TKI): inhibits VEGFR/PDGFR/FGFR/c-Kit, suppressing angiogenesis. Targets/pathways: Trop-2 on TNBC cells, topoisomerase I, PD-1 on T cells, VEGF/VEGFR and related pro-angiogenic signaling in tumor endothelium and stroma.